Wang Shuai, Wei Yan-Zhao, Yang Jianhong, Zhou Yuming, Zheng Yi
Beijing Anding Hospital, Capital Medical University, Beijing, China; Beijing Institute for Brain Disorders, Beijing 100001, China.
Beijing Anding Hospital, Capital Medical University, Beijing, China; Beijing Institute for Brain Disorders, Beijing 100001, China.
Eur J Paediatr Neurol. 2017 Jul;21(4):614-620. doi: 10.1016/j.ejpn.2017.03.003. Epub 2017 Apr 7.
The aim of this study was to evaluate the efficacy and safety of clonidine adhesive patch for tic disorders (TDs).
Medline, Embase, Cochrane central register of controlled trials and Chinese databases of CBM, CNKI were searched from inception to 08.2016 for randomized controlled studies (RCTs), open-label control studies of clonidine adhesive patch versus other medications or/and placebo for TDs. The cochrane Handbook for Systematic Reviews of Interventions was used to guide our study.
Six studies involving 1145 participants were included in this study. Among these studies, two study (N = 513 patients) used placebo as a control and four studies (N = 632 patients) used positive drug controls. The results of meta-analysis suggested that clonidine adhesive patch may be as effective as haloperidol or tiapride for TDs. Adverse events (AEs) were reported in all studies, and the most common AEs of clonidine adhesive patch were rash (8.9%), lightheadedness (8.0%), dry mouth (4.0%). The AEs of clonidine adhesive patch were slight.
These data provide moderate quality evidence that clonidine adhesive patch might be an effective and safe treatment option for TDs, and results from further trials are urgently needed to extend the evidence base.
本研究旨在评估可乐定贴片治疗抽动障碍（TDs）的疗效和安全性。
检索Medline、Embase、Cochrane对照试验中央注册库以及中国生物医学文献数据库（CBM）、中国知网（CNKI），检索时间从建库至2016年8月，查找关于可乐定贴片与其他药物或/和安慰剂治疗TDs的随机对照研究（RCTs）、开放标签对照研究。采用Cochrane干预系统评价手册指导本研究。
本研究纳入了6项涉及1145名参与者的研究。在这些研究中，2项研究（N = 513例患者）使用安慰剂作为对照，4项研究（N = 632例患者）使用阳性药物对照。荟萃分析结果表明，可乐定贴片治疗TDs的疗效可能与氟哌啶醇或硫必利相当。所有研究均报告了不良事件（AE），可乐定贴片最常见的AE为皮疹（8.9%）、头晕（8.0%）、口干（4.0%）。可乐定贴片的AE较轻。
这些数据提供了中等质量的证据，表明可乐定贴片可能是治疗TDs的一种有效且安全的选择，迫切需要进一步试验的结果来扩大证据基础。
